Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_assertion type Assertion NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_head.
- NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_assertion description "[A significant decrease of SOD (P < 0.05), GPX (P < 0.05) and nonsignificant decrease of CAT (P > 0.05), and TAS status (P > 0.05) were seen in T2DM patients with neuropathy compared to T2DM patients as well as controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_provenance.
- NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_assertion evidence source_evidence_literature NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_provenance.
- NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_assertion SIO_000772 22718504 NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_provenance.
- NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_assertion wasDerivedFrom befree-2016 NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_provenance.
- NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_assertion wasGeneratedBy ECO_0000203 NP991749.RAlL2i3M3fTS_dojkC2wMRrjnKNcIOr1NiY2EUGL3Y4N0130_provenance.